Methylene blue (methylthioninium chloride) is one of the oldest synthetic pharmaceutical compounds — first synthesized in 1876 and used as an antimalarial, antiseptic, and antidote for methemoglobinemia. In the last decade, it has gained significant attention as a mitochondrial-targeting compound with cognitive enhancement, neuroprotective, and antidepressant properties.

At low doses (0.5–4mg/kg), methylene blue improves mitochondrial efficiency by acting as an alternative electron carrier in the electron transport chain, increasing cellular ATP production. It also has potent antioxidant effects and inhibits monoamine oxidase A (MAO-A), contributing to antidepressant and mood-enhancing effects.

Pharmaceutical-grade compounded methylene blue is the only safe form for human therapeutic use — industrial grades contain heavy metal contaminants. It is FDA-approved only for IV treatment of methemoglobinemia; all other indications are off-label.

Mitochondrial Electron Carrier
Methylene blue cycles between oxidized (MB+) and reduced (MBH) forms, accepting electrons from NADH and donating them to cytochrome c in the electron transport chain. This bypasses dysfunctional ETC complexes (particularly Complex I), restoring electron flow and ATP synthesis in aging or damaged mitochondria.

MAO-A Inhibition
At therapeutic doses, methylene blue inhibits monoamine oxidase A, increasing synaptic serotonin, dopamine, and norepinephrine — producing antidepressant and mood-stabilizing effects that have been validated in clinical trials.

Antioxidant Effects
Methylene blue scavenges reactive oxygen species and superoxide radicals, reducing oxidative stress in mitochondria and neuronal tissue.

Cognitive / longevity (low dose): 0.5–4mg/kg orally; typically 10–80mg/day in capsule or solution form

Antidepressant range: 15–60mg daily (lower end avoids MAO-A interaction risk)

Important: High doses (>2mg/kg) may paradoxically inhibit mitochondrial function rather than enhance it — a hormetic dose-response curve applies

Start low (5–10mg) and assess tolerance. Blue discoloration of urine is expected and harmless.

Methylene blue has a hormetic dose-response curve — low doses enhance mitochondrial function while high doses can inhibit it. Start at 5–10mg and increase gradually. Expect blue/green urine discoloration — this is normal and harmless. Avoid combining with serotonergic medications due to MAO-A inhibition risk of serotonin syndrome.